Investor Area

Home / Investor Area / News / Appendix 4C
 

Appendix 4C

 

CLINUVEL PHARMACEUTICALS LTD, a global biopharmaceutical company focused on developing and delivering treatments for patients with a range of severe genetic and skin disorders, today announced its Appendix 4C – Quarterly Cashflow Report for the period 01 April to 30 June 2019.

 

Download PDF